Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reaffirmed by analysts at Needham & Company LLC in a research note issued to investors on Friday,Benzinga reports.

OMER has been the topic of several other reports. D. Boral Capital reissued a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Friday. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Omeros in a research report on Friday, June 27th. Finally, Wall Street Zen cut shares of Omeros from a “hold” rating to a “sell” rating in a research report on Friday, June 27th. One analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Omeros currently has an average rating of “Moderate Buy” and a consensus price target of $18.00.

Omeros Trading Up 7.0%

Shares of NASDAQ:OMER opened at $4.41 on Friday. Omeros has a 1 year low of $2.95 and a 1 year high of $13.60. The firm has a fifty day moving average price of $3.59 and a 200 day moving average price of $5.77. The stock has a market capitalization of $272.37 million, a PE ratio of -2.09 and a beta of 2.26.

Omeros (NASDAQ:OMER) last posted its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported ($0.53) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.02. The business had revenue of $28.60 million during the quarter, compared to analyst estimates of $0.31 million. On average, sell-side analysts forecast that Omeros will post -3.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in shares of Omeros during the 4th quarter worth about $124,000. Wealth Enhancement Advisory Services LLC bought a new stake in Omeros in the 1st quarter valued at about $579,000. Price T Rowe Associates Inc. MD boosted its holdings in Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 4,401 shares during the period. GAMMA Investing LLC boosted its holdings in Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 7,388 shares during the period. Finally, Cerity Partners LLC boosted its holdings in Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 2,600 shares during the period. Institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.